Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Allergan, Inc.    AGN   US0184901025

ALLERGAN, INC.

 (AGN)

14
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 

Allergan, Inc. : Allergan Gets Subpoena From Government Over Lap-Band System

05/07/2012| 06:11pm US/Eastern
Recommend:
0
   By Anjali Athavaley 
   Of  
 

Allergan Inc. (AGN) received a subpoena this month from the Department of Health and Human Services requesting documents related to the company's Lap-Band System for obesity, according to a filing.

Lap-Band is approved to help obese patients lose weight. It is inserted surgically through a small incision and placed at the top of the stomach. The inflatable band can be tightened or loosened to reduce or enlarge stomach capacity.

An Allergan spokeswoman declined to comment further.

Earlier this month, Allergan said its first-quarter earnings rose 45% on double-digit sales growth in its specialty-pharmaceuticals business. But sales in Allergan's obesity intervention category slipped 15.5% as high unemployment, lofty co-payments and rigid requirements from insurers pressured sales.

Last December, the U.S. Food and Drug Administration warned nine groups, mostly surgical centers in California, that if they continue misleading advertising for Lap-Band, they could face monetary penalties and have inventory seized. The FDA made no allegations against Allergan at the time.

Allergan shares were up fractionally to $93.79 in after-hours trading Monday. The stock is up nearly 7% so far this year.

-By Anjali Athavaley, Dow Jones Newswires; 212-416-4912; anjali.athavaley@dowjones.com

Recommend :
0
Partner Area
React to this article
 
Latest news on ALLERGAN, INC.
3d ago ALLERGAN, INC.: ex-dividend day
05/02 ALLERGAN, INC.: New Guidelines Recommend Medical and Surgical Therapies Added t..
05/02 ALLERGAN, INC.: FDA Advisory Committee Unanimously Recommends JUVÉDERM VOLUMA? ..
05/01DJAllergan Reports Drug Development Delay, Lower Profits
05/01DJAllergan Reports Drug Development Delay, Lower Profits
05/01DJALLERGAN, INC.: Allergan 1st-Quarter Profit Slumps Amid Expected Loss on Sale o..
05/01 ALLERGAN, INC.: Allergan Reports First Quarter 2013 Operating Results
04/30 ALLERGAN, INC.: Allergan Announces Death of Stephen J. Ryan, M.D.
04/26DJALLERGAN, INC.: FDA Warns of Counterfeit Botox
04/16DJALLERGAN, INC.: FDA Doesn't Approve Allergan's Levadex for Migraines
Advertisement
Chart
Duration : Period :
Allergan, Inc. Technical Analysis Chart | AGN | US0184901025 | 4-Traders
Income Statement Evolution
Allergan, Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.